Skip to content

Association of YTHDF1 and YTHDF2 expression levels with clinical prognosis and immune function in non-small cell lung cancer

Association of YTHDF1 and YTHDF2 expression levels with clinical prognosis and immune function in non-small cell lung cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600118358
Enrollment
Unknown
Registered
2026-02-04
Start date
2025-04-10
Completion date
Unknown
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung squamous cell carcinoma

Interventions

Adjacent non-cancerous tissue group:NA
Lung squamous cell carcinoma group :NA

Sponsors

The First Affiliated Hospital of the Baotou Medical College of Inner Mongolia University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. The history of present illness, personal history, family history, and physical examination data are well-documented; tissue-microarray pathological materials are complete, and the diagnosis of lung squamous cell carcinoma is confirmed. 2. Patients who had not received any neoadjuvant chemoradiotherapy prior to the study.

Exclusion criteria

Exclusion criteria: 1. Patients have concurrent and uncontrolled infections; 2. The patient had previously received any form of antitumor therapy; 3. The patient is pregnant or breastfeeding.

Design outcomes

Primary

MeasureTime frame
Expression levels of YTHDF1 and YTHDF2 proteins;

Countries

China

Contacts

Public ContactWang Fengyun

The First Affiliated Hospital of the Baotou Medical College of Inner Mongolia University of Science and Technology

wfy2826@163.com+86 472 217 8217

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026